Homeobox D9 Drives the Malignant Phenotypes and Enhances the Programmed Death Ligand-1 Expression in Non-small Cell Lung Cancer Cells Via Binding to Angiopoietin-2 Promoter

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2023 Mar 13

PMID 36907878

Authors

Jiabei He

Mengjia Jiang

Jing Liu

Ruiping Zhu

Weipeng Lv

Ruiqing Lian

Yang Yang

Ruoyu Wang

Affiliations

Soon will be listed here.

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. Homeobox D9 (HOXD9), a member of the HOX family of transcription factors, plays a driver role in development of multiple cancers. Angiopoietin-2 (ANGPT2) is reportedly to facilitate angiogenesis, growth and metastasis in various cancers, including lung cancer. In addition, blocking ANGPT2 can effectively improve cancer immunotherapy via downregulation of Programmed death ligand-1 (PD-L1). The purpose of this study was to elucidate the role of HOXD9 in NSCLC and whether ANGPT2 is required for HOXD9-mediated malignant behaviors of NSCLC cells. By performing a series of in vitro functional experiments, we found that knockdown of HOXD9 induced proliferative inhibition, cell cycle G1 arrest, apoptosis, migratory suppression and invasive repression of NSCLC cells. Reduced PD-L1 expression in NSCLC cells was observed after HOXD9 silencing. Besides, HOXD9 deletion decreased the expression of ANGPT2 in NSCLC cells. In line with this, HOXD9 overexpression led to opposite alteration in NSCLC cells. Mechanistically, ANGPT2 was transcriptionally activated by HOXD9. Forced expression of ANGPT2 significantly regulated HOXD9-mediated malignant phenotypes, and enhanced PD-L1 expression of NSCLC cells. Our results expressing HOXD9 may function as an oncogene in NSCLC via trans-activation of ANGPT2.

Citing Articles

Establishing patient-derived tumor organoids of bone metastasis from lung adenocarcinoma reveals the transcriptomic changes underlying denosumab treatment.

Hu X, Wu H, Hu K, Kang Y, Hua G, Cheng M Clin Exp Metastasis. 2024; 42(1):8.

PMID: 39739069 DOI: 10.1007/s10585-024-10321-2.

ESM1 facilitates the EGFR/HER3-triggered epithelial-to-mesenchymal transition and progression of gastric cancer via modulating interplay between Akt and angiopoietin-2 signaling.

Yang Y, Ho K, Pan K, Hua K, Tung M, Ku C Int J Biol Sci. 2024; 20(12):4819-4837.

PMID: 39309430 PMC: 11414391. DOI: 10.7150/ijbs.100276.

HOXD9/miR-451a/PSMB8 axis is implicated in the regulation of cell proliferation and metastasis via PI3K/AKT signaling pathway in human anaplastic thyroid carcinoma.

Zhong Y, Yu F, Yang L, Wang Y, Liu L, Jia C J Transl Med. 2023; 21(1):817.

PMID: 37974228 PMC: 10652604. DOI: 10.1186/s12967-023-04538-0.

HOXD9 is a potential prognostic biomarker involved in immune microenvironment of glioma.

Xu S, Xiao H, Song T, Zeng Y, Wei C, Chen T J Cancer Res Clin Oncol. 2023; 149(16):14911-14926.

PMID: 37603105 DOI: 10.1007/s00432-023-05275-z.

References

Wu X, Giobbie-Hurder A, Liao X, Connelly C, Connolly E, Li J . Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunol Res. 2016; 5(1):17-28. PMC: 5215959. DOI: 10.1158/2326-6066.CIR-16-0206. View

Takeuchi M, Doi T, Obayashi K, Hirai A, Yoneda K, Tanaka F . Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer. Immunol Lett. 2018; 196:155-160. DOI: 10.1016/j.imlet.2018.01.007. View

Sa H, Song P, Ma K, Gao Y, Zhang L, Wang D . Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer. Onco Targets Ther. 2019; 12:8151-8159. PMC: 6781597. DOI: 10.2147/OTT.S222412. View

Wen D, Wang L, Tan S, Tang R, Xie W, Liu S . HOXD9 aggravates the development of cervical cancer by transcriptionally activating HMCN1. Panminerva Med. 2020; 64(4):532-536. DOI: 10.23736/S0031-0808.20.03911-7. View

Holland P . Evolution of homeobox genes. Wiley Interdiscip Rev Dev Biol. 2013; 2(1):31-45. DOI: 10.1002/wdev.78. View

Chang J, Hu X, Nan J, Zhang X, Jin X . HOXD9‑induced SCNN1A upregulation promotes pancreatic cancer cell proliferation, migration and predicts prognosis by regulating epithelial‑mesenchymal transformation. Mol Med Rep. 2021; 24(5). PMC: 8477178. DOI: 10.3892/mmr.2021.12459. View

Venugopalan A, Lynberg M, Cultraro C, Nguyen K, Zhang X, Waris M . SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma. Oncogene. 2021; 40(18):3331-3346. PMC: 8514158. DOI: 10.1038/s41388-021-01764-y. View

Reck M, Garassino M, Imbimbo M, Shepherd F, Socinski M, Shih J . Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018; 120:62-69. DOI: 10.1016/j.lungcan.2018.03.025. View

Bupathi M, Kaseb A, Janku F . Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives. Onco Targets Ther. 2014; 7:1927-32. PMC: 4211614. DOI: 10.2147/OTT.S46457. View

10.

Pawelczyk K, Piotrowska A, Ciesielska U, Jablonska K, Gletzel-Plucinska N, Grzegrzolka J . Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers. Int J Mol Sci. 2019; 20(4). PMC: 6413136. DOI: 10.3390/ijms20040824. View

11.

Qiu L, Chen J, Yang X, Fang M, Zheng W, Dong Z . [Abnormal expression of angiopoietin-2 associated with invasion, metastasis and prognosis of lung cancer]. Zhonghua Yi Xue Za Zhi. 2018; 98(16):1261-1266. DOI: 10.3760/cma.j.issn.0376-2491.2018.16.015. View

12.

Imanishi Y, Hu B, Jarzynka M, Guo P, Elishaev E, Bar-Joseph I . Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway. Cancer Res. 2007; 67(9):4254-63. PMC: 2881574. DOI: 10.1158/0008-5472.CAN-06-4100. View

13.

Lin C, Cho C, Bai S, Liu J, Kuo T, Wang L . ADAM9 promotes lung cancer progression through vascular remodeling by VEGFA, ANGPT2, and PLAT. Sci Rep. 2017; 7(1):15108. PMC: 5678093. DOI: 10.1038/s41598-017-15159-1. View

14.

Liu D, Gu Z, Cao X, Liu H, Li J . Immunocytochemical detection of HoxD9 and Pbx1 homeodomain protein expression in Chinese esophageal squamous cell carcinomas. World J Gastroenterol. 2005; 11(10):1562-6. PMC: 4305705. DOI: 10.3748/wjg.v11.i10.1562. View

15.

Wang L, Tsai H, Cheng Y, Lin C, Huang Y, Tsai C . CTGF promotes osteosarcoma angiogenesis by regulating miR-543/angiopoietin 2 signaling. Cancer Lett. 2017; 391:28-37. DOI: 10.1016/j.canlet.2017.01.013. View

16.

Cavallaro U, Christofori G . Molecular mechanisms of tumor angiogenesis and tumor progression. J Neurooncol. 2001; 50(1-2):63-70. DOI: 10.1023/a:1006414621286. View

17.

Zhu H, Dai W, Li J, Xiang L, Wu X, Tang W . HOXD9 promotes the growth, invasion and metastasis of gastric cancer cells by transcriptional activation of RUFY3. J Exp Clin Cancer Res. 2019; 38(1):412. PMC: 6755711. DOI: 10.1186/s13046-019-1399-1. View

18.

Hayashi S, Iwata T, Imagawa R, Sugawara M, Chen G, Tanimoto S . Transcription Factor Homeobox D9 Drives the Malignant Phenotype of HPV18-Positive Cervical Cancer Cells via Binding to the Viral Early Promoter. Cancers (Basel). 2021; 13(18). PMC: 8470817. DOI: 10.3390/cancers13184613. View

19.

Zhang W, Jin J, Wang Y, Fang L, Min L, Wang X . PD-L1 regulates genomic stability via interaction with cohesin-SA1 in the nucleus. Signal Transduct Target Ther. 2021; 6(1):81. PMC: 7904913. DOI: 10.1038/s41392-021-00463-0. View

20.

Hirao N, Iwata T, Tanaka K, Nishio H, Nakamura M, Morisada T . Transcription factor homeobox D9 is involved in the malignant phenotype of cervical cancer through direct binding to the human papillomavirus oncogene promoter. Gynecol Oncol. 2019; 155(2):340-348. DOI: 10.1016/j.ygyno.2019.08.026. View